Brief: Positive Results From Human PK Study Assessing Orexo's Intranasal Nalmefene Formulations For Opioid Overdose Reversal
June 30 (Reuters) - Orexo AB ORX.ST :
* POSITIVE RESULTS FROM HUMAN PK STUDY ASSESSING OREXO'S
INTRANASAL NALMEFENE FORMULATIONS FOR OPIOID OVERDOSE REVERSAL
* PRELIMINARY RESULTS INDICATE EXTENSIVE AND RAPID
ABSORPTION
ACROSS ALL THREE OX125 FORMULATIONS AS WELL AS GOOD
TOLERABILITY, SUPPORTING VIABILITY OF OX125 AS A RESCUE
MEDICATION FOR OPIOID OVERDOSE
Source text for Eikon: ID:nWkr2WXfTl
Further company coverage: ORX.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 587785110;))
Recent news on Orexo AB
See all newsBrief: Orexo Announces Positive Outcome From An In-Vivo Study Of Ox390
Brief: Orexo Announces Positive Outcome From An In-Vivo Study Of Ox390
Brief: Orexo Announces Positive Pre-Clinical Data For Nasal Atipamezole Using Amorphox Technology
Brief: Orexo AB Reports Q1 2026 Net Revenue Of Sek 5.0 Million
Sweden's Orexo Q1 revenue drops, net loss widens